	1.	Article Title: Neuropsychological outcomes in children and adolescents following anti-NMDA receptor encephalitis
	•	Line(s): 1-2
	•	Section: Title
	•	Quote(s): “Neuropsychological outcomes in children and adolescents following anti-NMDA receptor encephalitis”
	2.	Publication Year: 2022
	•	Line(s): 5
	•	Section: Journal Citation
	•	Quote(s): “Child Neuropsychology, 28:2, 212-223, DOI: 10.1080/09297049.2021.1965110”
	3.	Region: North America
	•	Line(s): 10-12
	•	Section: Author Affiliations
	•	Quote(s): “Children’s Medical Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; Children’s Healthcare of Atlanta, Atlanta, Georgia”
	4.	Country: United States
	•	Line(s): 10-12
	•	Section: Author Affiliations
	•	Quote(s): “Children’s Medical Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; Children’s Healthcare of Atlanta, Atlanta, Georgia”
	5.	Study Coverage Area: Multi-center study (Dallas, Texas & Atlanta, Georgia)
	•	Line(s): 10-12
	•	Section: Author Affiliations
	•	Quote(s): “Children’s Medical Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; Children’s Healthcare of Atlanta, Atlanta, Georgia”
	6.	Study Design: Retrospective chart review
	•	Line(s): 30-34
	•	Section: Methods
	•	Quote(s): “This was a multi-centered retrospective chart review.”
	7.	Population Cohort: Pediatric patients diagnosed with anti-NMDAR encephalitis
	•	Line(s): 27-30
	•	Section: Methods
	•	Quote(s): “We identified 23 pediatric patients who were, on average, 18.5 months from diagnosis.”
	8.	Population Characteristics: Median age at diagnosis 8.8 years, 65.2% female
	•	Line(s): 93-95
	•	Section: Results
	•	Quote(s): “The sample consisted of eight males (34.8%) and 15 females (65.2%). The mean age at diagnosis was 8.8 years.”
	9.	Data Source: Hospital neuropsychological records
	•	Line(s): 30-34
	•	Section: Methods
	•	Quote(s): “We identified 23 pediatric patients who underwent comprehensive neuropsychological assessment.”
	10.	Prospective or Retrospective: Retrospective
	•	Line(s): 30
	•	Section: Methods
	•	Quote(s): “This was a multi-centered retrospective chart review.”
	11.	Sites or Centers Involved: Two centers (Dallas & Atlanta)
	•	Line(s): 10-12
	•	Section: Author Affiliations
	•	Quote(s): “Children’s Medical Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; Children’s Healthcare of Atlanta, Atlanta, Georgia”
	12.	Study Duration: 2013–2018
	•	Line(s): 30-32
	•	Section: Methods
	•	Quote(s): “Between 2013 and 2018, a total of 50 patients were identified with a confirmed diagnosis of ANMDARE.”
	13.	Population Ethnicity: 47.8% Latinx, 39.1% Black, 8.7% White, 4.3% Asian
	•	Line(s): 93-95
	•	Section: Results
	•	Quote(s): “47.8% of the patients were Latinx, 39.1% were Black, 8.7% were White, and 4.3% were Asian.”
	14.	Disease Analysis: Anti-NMDAR encephalitis
	•	Line(s): 27-30
	•	Section: Methods
	•	Quote(s): “We identified 23 pediatric patients who were, on average, 18.5 months from diagnosis.”
	15.	Classification or Diagnosis: Diagnosis confirmed by presence of NMDAR antibodies in serum and/or CSF
	•	Line(s): 27-30
	•	Section: Methods
	•	Quote(s): “Inclusion criteria consisted of children ages 0 to 18 with confirmed NMDA antibodies in the serum or cerebrospinal fluid (CSF).”
	16.	Diagnosis Criteria Details: NR
	17.	Disease Phase: NR
	18.	Cohort Age Group: Pediatric (ages 0-18 years)
	•	Line(s): 27-30
	•	Section: Methods
	•	Quote(s): “Inclusion criteria consisted of children ages 0 to 18 with confirmed NMDA antibodies.”
	19.	Female Percentage in Cohort: 65.2%
	•	Line(s): 93-95
	•	Section: Results
	•	Quote(s): “The sample consisted of eight males (34.8%) and 15 females (65.2%).”
	20.	Patient Number of Autoimmune Encephalitis: 23 patients
	•	Line(s): 93-95
	•	Section: Results
	•	Quote(s): “We identified 23 pediatric patients who were, on average, 18.5 months from diagnosis.”
	•	Subtypes and Patient Numbers:
	•	Anti-NMDAR: 23 patients
	21.	Follow-up Period: Mean 18.5 months (range: 9–32 months)
	•	Line(s): 213-215
	•	Section: Results
	•	Quote(s): “Neuropsychological evaluations were completed between 9 and 32 months post diagnosis (mean time since diagnosis = 18.5 months).”
	22.	Age of Patients by Subtype:
	•	Anti-NMDAR:
	•	Mean: NR
	•	SD: NR
	•	Median: NR
	•	IQR: NR
	23.	Age of Diagnosis by Subtype: 
	•	Anti-NMDAR:
	•	Mean: 8.8 years
	•	SD: ±5.02 years
	•	Median: NR
	•	IQR: NR